Posts tagged “BDSI”

November 16, 2011

Premium Lock BioDelivery Sciences runs short on cash, time

Painkillers The company has $15.1 million in cash. But the Raleigh-based firm is working on two clinical-stage drug programs and it doesn't have enough money to pay for both of them.

Updated November 11, 2011

Premium Lock Raleigh drug firm BDSI takes aim at $1B opioid drug market

BDSI "We believe we are on course to become one of the first products to compete with Suboxone, a product with sales in excess of a billion dollars annually and currently without competition," CEO Mark Sirgo says.

September 29, 2011

Premium Lock BioDelivery Sciences not phased by drug's trial failure

BDSI The Raleigh-based company also says potential partners are still interested in the pain reliver.

September 29, 2011

Premium Lock BioDelivery Sciences drug candidate fails in trial

BDSI The chronic pain reliver didn't perform better than a placebo in a Phase 3 clinical trial, but the Raleigh company isn'r giving up.

August 24, 2011

Premium Lock BioDelivery Sciences prepares for launch of pain killer in Canada

BDSI The Raleigh-based drug firm gears to sell breakthrough cancer pain reliver after working through production problems.

October 20, 2010

Premium Lock BioDelivery Sciences secures European approval for pain killer

BDSI The decision means $2.5 million in milestone payment for the Raleigh firm.

September 7, 2010

Premium Lock Former exec at Closure Medical joins BioDelivery Sciences

BDSI Benny Ward takes over as business and strategic development director at the drug delivery technology development firm.

May 10, 2010

Premium Lock BioDelivery Sciences wins Canadian approval for painkiller

BDSI The Raleigh-based firm can now sell its “breakthrough” pain killer drug outside of the U.S. It is seeking approval to sell Onsolis in Europe.

Updated April 20, 2010

Premium Lock BioDelivery Sciences stock plunges after $10M deal disclosed

BDSI The announced sale sends BDSI shares down 14 percent from Monday’s closing price of $4.21 per share.

September 2, 2009

Premium Lock BioDelivery Sciences closing lab in New Jersey, cutting five jobs

BDSI Chief science officer is also leaving drug development firm, which recently won FDA approval for its first product.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith